
|Articles|July 31, 2006
Fourth indication approved for gemcitabine
Women with recurrent ovarian cancer will now have a new therapy option. Gemcitabine (Gemzar, Lilly) has been approved for use in combination with carboplatin for advanced ovarian cancer that has relapsed at least six months after initial therapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
2
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
3
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
4
Once Weekly Oral HIV Regimen Maintains Suppression Through Week 48
5






























